Sally Beauty Holdings (SBH) Earnings Analysis
Sally Beauty Holdings (SBH) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it beat with EPS 0.44 USD vs 0.41 USD est (+7.3%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E 7.79.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SBH next report earnings?
No confirmed upcoming earnings date is currently scheduled for SBH. This page updates as the calendar is published.
SBH earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | 0.44 USD | 0.41 USD | +7.3% | Beat |
| 2026-02-09 | 0.48 USD | 0.47 USD | +2.1% | Beat |
| 2025-11-13 | 0.55 USD | 0.478 USD | +15.1% | Beat |
| 2025-05-12 | 0.42 USD | 0.39 USD | +7.7% | Beat |
| 2025-02-13 | 0.43 USD | 0.43 USD | 0% | Beat |
| 2024-11-14 | 0.5 USD | 0.47 USD | +6.4% | Beat |
Beat rate: 6/6 (100%) over reported quarters with consensus data.
SBH valuation and analyst view
| Trailing P/E | 7.79 |
|---|---|
| Trailing EPS | 1.901 USD |
| Price / book | 1.69 |
| Dividend yield | 0.00% |
| Market cap | 1.42B |
| Analyst consensus | Hold (9 buy / 17 hold / 4 sell) |
| Avg price target | 16.07 USD |
Related research pages
Frequently asked questions
When is Sally Beauty Holdings (SBH)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for SBH. This page updates as the calendar is published.
Did SBH beat earnings last quarter?
In its 2026-05-11 report, SBH posted EPS of 0.44 USD versus a 0.41 USD estimate — a beat of 7.3%.
What is SBH's earnings track record?
Over the last 6 reported quarters with consensus data, SBH beat estimates 6 times (100%).
What is SBH's current P/E ratio and EPS?
SBH trades at a trailing P/E of 7.79 on trailing EPS of 1.9012995337392868 USD.
What do analysts rate SBH?
Analyst consensus is "Hold" across 30 ratings (0 strong buy, 9 buy, 17 hold, 4 sell, 0 strong sell). Average 12-month price target: 16.07 USD.